BWX Technologies (BWXT) Q2 2024 earnings summary

Executive summary

• Q2 2024 results exceeded expectations, with revenue up 11% year-over-year to $681.5 million, driven by strong organic growth in both Government and Commercial Operations.

• Adjusted EBITDA rose 18% to $126 million, and non-GAAP EPS increased 26% to $0.82, aided by margin performance and a lower tax rate from Canadian legislation.

• Net income for Q2 2024 was $73.0 million, up from $58.6 million in Q2 2023.

• Key business wins included a 20-year NNSA Pantex Plant contract and progress in microreactor and Actinium-225 initiatives.

• Recent legislative and industry developments are supporting increased demand for nuclear solutions in security, clean energy, and medical markets.

Financial highlights

• Q2 2024 revenue was $681.5 million, up 11% year-over-year; adjusted EBITDA was $126 million, up 18%; non-GAAP EPS was $0.82, up 26%.

• Net income for Q2 2024 was $73.0 million; operating income was $98.8 million, up $12.1 million from the prior year.

• Free cash flow for Q2 was $36 million; year-to-date free cash flow was $38 million, up from a $2 million use in the first half of 2023.

• CapEx for Q2 was $30.4 million, with full-year CapEx expected to match last year's $151 million.

• Q2 2024 gross margin was $168.2 million (24.7%); operating margin was 14.5%.

Outlook and guidance

• 2024 revenue guidance reaffirmed at over $2.6 billion, with adjusted EBITDA expected around $500 million and a margin of ~19%.

• Non-GAAP EPS guidance narrowed and raised to $3.10–$3.20 for 2024.

• Free cash flow guidance for 2024 remains at $225–$250 million.

• 68% of $3.53 billion backlog expected to convert to revenue by end of 2025.

• Sufficient liquidity and borrowing capacity to meet cash requirements for the next 12 months and beyond.